CRASH-2 (Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage) intracranial bleeding study: the effect of tranexamic acid in traumatic brain injury--a nested randomised, placebo-controlled trial

P Perel; R Al-Shahi Salman; T Kawahara; Z Morris; D Prieto-Merino; I Roberts; P Sandercock; H Shakur; J Wardlaw

doi:10.3310/hta16130

CRASH-2 (Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage) intracranial bleeding study: the effect of tranexamic acid in traumatic brain injury--a nested randomised, placebo-controlled trial

P Perel, R Al-Shahi Salman, T Kawahara, Z Morris, D Prieto-Merino, I Roberts, P Sandercock, H Shakur, J Wardlaw

Research output: Contribution to journal › Article › peer-review

Abstract / Description of output

Tranexamic acid (TXA) has been shown to reduce blood loss in surgical patients and the risk of death in patients with traumatic bleeding, with no apparent increase in vascular occlusive events. These findings raise the possibility that it might also be effective in traumatic brain injury (TBI).

Original language	English
Pages (from-to)	iii-xii, 1-54
Journal	Health Technology Assessment
Volume	16
Issue number	13
DOIs	https://doi.org/10.3310/hta16130
Publication status	Published - 2012

Access to Document

10.3310/hta16130

Fingerprint

Dive into the research topics of 'CRASH-2 (Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage) intracranial bleeding study: the effect of tranexamic acid in traumatic brain injury--a nested randomised, placebo-controlled trial'. Together they form a unique fingerprint.

Cite this

Perel, P., Salman, R. A.-S., Kawahara, T., Morris, Z., Prieto-Merino, D., Roberts, I., Sandercock, P., Shakur, H., & Wardlaw, J. (2012). CRASH-2 (Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage) intracranial bleeding study: the effect of tranexamic acid in traumatic brain injury--a nested randomised, placebo-controlled trial. Health Technology Assessment, 16(13), iii-xii, 1-54. https://doi.org/10.3310/hta16130

@article{e1e0af3fd8b34800a2c01431ce750ad4,

title = "CRASH-2 (Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage) intracranial bleeding study: the effect of tranexamic acid in traumatic brain injury--a nested randomised, placebo-controlled trial",

abstract = "Tranexamic acid (TXA) has been shown to reduce blood loss in surgical patients and the risk of death in patients with traumatic bleeding, with no apparent increase in vascular occlusive events. These findings raise the possibility that it might also be effective in traumatic brain injury (TBI).",

author = "P Perel and Salman, {R Al-Shahi} and T Kawahara and Z Morris and D Prieto-Merino and I Roberts and P Sandercock and H Shakur and J Wardlaw",

year = "2012",

doi = "10.3310/hta16130",

language = "English",

volume = "16",

pages = "iii--xii, 1--54",

journal = "Health Technology Assessment",

issn = "1366-5278",

publisher = "NIHR Health Technology Assessment Programme",

number = "13",

}

Perel, P, Salman, RA-S, Kawahara, T, Morris, Z, Prieto-Merino, D, Roberts, I, Sandercock, P, Shakur, H & Wardlaw, J 2012, 'CRASH-2 (Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage) intracranial bleeding study: the effect of tranexamic acid in traumatic brain injury--a nested randomised, placebo-controlled trial', Health Technology Assessment, vol. 16, no. 13, pp. iii-xii, 1-54. https://doi.org/10.3310/hta16130

CRASH-2 (Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage) intracranial bleeding study: the effect of tranexamic acid in traumatic brain injury--a nested randomised, placebo-controlled trial. / Perel, P; Salman, R Al-Shahi; Kawahara, T et al.
In: Health Technology Assessment, Vol. 16, No. 13, 2012, p. iii-xii, 1-54.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - CRASH-2 (Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage) intracranial bleeding study: the effect of tranexamic acid in traumatic brain injury--a nested randomised, placebo-controlled trial

AU - Perel, P

AU - Salman, R Al-Shahi

AU - Kawahara, T

AU - Morris, Z

AU - Prieto-Merino, D

AU - Roberts, I

AU - Sandercock, P

AU - Shakur, H

AU - Wardlaw, J

PY - 2012

Y1 - 2012

N2 - Tranexamic acid (TXA) has been shown to reduce blood loss in surgical patients and the risk of death in patients with traumatic bleeding, with no apparent increase in vascular occlusive events. These findings raise the possibility that it might also be effective in traumatic brain injury (TBI).

AB - Tranexamic acid (TXA) has been shown to reduce blood loss in surgical patients and the risk of death in patients with traumatic bleeding, with no apparent increase in vascular occlusive events. These findings raise the possibility that it might also be effective in traumatic brain injury (TBI).

UR - http://www.scopus.com/inward/record.url?scp=84859136754&partnerID=8YFLogxK

U2 - 10.3310/hta16130

DO - 10.3310/hta16130

M3 - Article

C2 - 22417901

SN - 1366-5278

VL - 16

SP - iii-xii, 1-54

JO - Health Technology Assessment

JF - Health Technology Assessment

IS - 13

ER -

Perel P, Salman RAS, Kawahara T, Morris Z, Prieto-Merino D, Roberts I et al. CRASH-2 (Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage) intracranial bleeding study: the effect of tranexamic acid in traumatic brain injury--a nested randomised, placebo-controlled trial. Health Technology Assessment. 2012;16(13):iii-xii, 1-54. doi: 10.3310/hta16130

CRASH-2 (Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage) intracranial bleeding study: the effect of tranexamic acid in traumatic brain injury--a nested randomised, placebo-controlled trial

Abstract / Description of output

Access to Document

Other files and links

Fingerprint

Cite this